Market Overview

Credit Suisse Reiterates Intercept's Lofty $200 Price Target; Ocaliva Will Be A 'Surprisingly Solid Launch'

Share:
Credit Suisse Reiterates Intercept's Lofty $200 Price Target; Ocaliva Will Be A 'Surprisingly Solid Launch'
Related ICPT
Benzinga's Top Upgrades, Downgrades For January 20, 2017
Jefferies' Picks For 2017's Most And Least Likely Biotech M&A Targets

Credit Suisse's Alethia Young reiterated her Outperform rating on Intercept Pharmaceuticals Inc (NASDAQ: ICPT) with a price target of $200.00. The reiteration came after Intercept's Octavia product passed FCC approval for treating Patients with PBC.

"Ocaliva pricing of $69,350 was roughly in-line with our expectations," said Young. The analyst was happy to see the FCC action, as Intercept's "first drug approval is a key de-risking point for companies watching the FXR space."

Related Link: Cowen Lifts Intercept's Price Target To $215 Following Ocaliva Approval

The Credit Suisse analyst thinks the company's pricing, preparation and market strategy are "lining up for what could be a surprisingly solid launch." Additionally, Young expects little competition for patients from ongoing placebo controlled COBALT trials.

Largely due to the FCC approval, Intercept Pharmaceuticals was trading up 3.45 percent at the time of writing.

Latest Ratings for ICPT

DateFirmActionFromTo
Jan 2017NeedhamDowngradesBuyHold
Aug 2016OppenheimerMaintainsOutperform
Jul 2016Cantor FitzgeraldInitiates Coverage onSell

View More Analyst Ratings for ICPT
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas News Health Care Price Target Reiteration Analyst Ratings Best of Benzinga

 

Related Articles (ICPT)

View Comments and Join the Discussion!